Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-03-20
2007-03-20
Andres, Janet L. (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200
Reexamination Certificate
active
08735010
ABSTRACT:
Disclosed is the characterization and purification of DNA encoding polypeptides useful for the stimulation of glial cell mitogenesis. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides in the prevention or treatment of multiple sclerosis.
REFERENCES:
patent: 4767628 (1988-08-01), Hutchinson
patent: 4935341 (1990-06-01), Bargmann et al.
patent: 4968603 (1990-11-01), Slamon et al.
patent: 5237056 (1993-08-01), Fischbach
patent: 5367060 (1994-11-01), Vandlen et al.
patent: WO8906692 (1989-07-01), None
patent: WO9014357 (1990-11-01), None
patent: WO9115230 (1991-10-01), None
patent: WO9118921 (1991-12-01), None
patent: WO9212174 (1992-07-01), None
patent: WO9322339 (1993-11-01), None
patent: WO9322424 (1993-11-01), None
Weinshenker,Ann. Neurol., vol. 36, pp. 56-511, 1994.
Hauser,Ann. Neurol., vol. 36, pp. 5157-5162, 1994.
Farukawa et al.,Cerebrovascular and Brain Metabolism Reviews, vol. 2, pp. 328-344, 1990 (Abstract only).
Webster's II New Riverside University Dictionary, The Riverside Publishing Company, 1988, p. 608.
Webster's II New Riverside University Dictionary, The Riverside Publishing Company, 1988, p. 944.
Benveniste, E.N. et al., P.N.A.S., “Purification and characterization of a human T-lymphocyte-derived glial growth promoting factor”, 82: 3930-3934, Jun. 1985.
Kimura, H. et al., “Nature, Structure, expression and function of a Schwannama derived growth factor”, 348: 257-260, Nov. 15, 1990.
Falls et al., Cell, ARIA, a Protein that stimulates acetypcholine receptor synthesis, is a member of the Neu Ligand family, 72: 801-815 (1993).
Brookes et al., “Purification and Preliminary Characterization of a Glial Growth Factor from the Bovine Pituitary”, J. Biol. Chem. 255: 18, 8374-8377 (Sep. 1980).
Brookes et al., “The neuron as a source of mitogen: its influence on the proliferation of glial and non-neural cells”, Garrod and Feldman eds, pp. 309-327 (1980).
Lemke et al. “An Immunochemical Approach to the Purification and Characterization of Glial Growth Factor”, Monoclonal Antibodies to Neural Antigens, McKay, Raff and Reichardt eds. pp. 133-140 (1981).
Lemke et al., “Identification and Purification of Glial Growth Factor”, J. Neuroscience, vol. 4, No. 1, pp. 75-83 (Jan. 1984).
Brockes, “Assay and Isolation of Glial Growth Factor from the Bovine Pituitary”, Methods in Enzymology, 147: 217-225 (1987).
Davis et al., “Platelet-derived Growth Factors and Fibroblasts Growth Factors Are Mitogens for Rat Schwann Cells”, J. Cell Biology 110: 1353 (Apr. 1990).
Peles et al., “Isolation of the Neu/HER-2 Stimulatory Ligand: A 44 KC Glyco-protein That Induces Differentiation of Mammary Tumor Cells”, Cell 69: 205 (Apr. 1992).
Lupu et al., “Direct Intera-tion of a Ligand for the erbB2 Oncogene Product with the EGF Receptor and p185erbB2”, Science 249: 1552 (Sep. 1990).
Yarden et al., “Biochemical Analysis of the Ligand for the neu Oncogenic Receptor”, Biochemistry 30: 3543 (1991).
Dobasni et al., “Characterization of a neu/-cerbB-2 protein-specific activating factor”, P.N.A.S., U.S.A. 88: 8582 (Oct. 1991).
Tarakhovsky et al., “A 25 kDa polypeptide in the Ligand for p185neu and is secreted by activated macrophages”, Oncogene 6: 2187 (1991).
Davis et al., “Isolation and characterization of a neu protein-specific activating factor from human ATL-2 cell conditioned medium”, Biochem. Biophys. Research Communications 179: 1536 (Sep. 1991).
Huang et al. “Purification and Characterization of the neu/erb B2 Ligand-Growth Factor from Bovine Kidney”, J. Biol. Chem. 257: 11508 (Jun. 1992).
Lupu et al., “Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses”, P.N.A.S., U.S.A. 89: 2287 (Mar. 1992).
Holes et al., “Identification of Heregulin, a Specific Activator of p185erbB2”, Science 256: 1205 (May 1992).
Wen et al., “Neu Differentiation Factor: A Transmembrane Glycoprotein Containing an EGF Domain and an Immunoglobulin Homology Unit”, Cell 69: 559 (May 1992).
Yarden, “Growth Factor Receptor Tyrosine Kinases”, Ann. Rev. Biochem. 57: 443-478 (1988).
Chen Mario Su
Goodearl Andrew
Hiles Ian
Marchioni Mark
Minghetti Luisa
Acorda Therapeutics, Inc.
Andres Janet L.
Gucker Stephen
Klauber & Jackson LLC
Ludwig Institute for Cancer Research
LandOfFree
Methods for treating multiple sclerosis with GGF-related... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating multiple sclerosis with GGF-related..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating multiple sclerosis with GGF-related... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3745940